As a result of the investigations carried out by the Translational Genomics Group, different spin-off companies have been created, covering different fields, for further experimentation.
|
Spin-off Companies
The Translational Genomics laboratory has a long-standing experience in the research of genetic diseases, which includes mastering the molecular tools required for genetic testing in humans. This experience led to the establishment in 2009 of the Institute of Medical Genetics (IMEGEN) as a company specialized in the diagnostic of the human genetic diseases and counseling to patients. Since then, the company has become an international leader in this field and, currently, can detect more than 4000 disease-causing molecular errors in the human genome.
|
Based on proprietary results generated in our laboratory and reported in Cerro-Herreros et al. 2018, Arthex Biotech was established in mid 2019 with the mission to transform this proof-of-concept result into an actual treatment for myotonic dystrophy patients. This involves the testing of hundreds of oligonucleotide variants able to block the activity of miR-23b and miR-218 in in vitro and in vivo models, the identification of a lead compound and the preclinical verification of safety in humans under strict conditions set by the medicine regulatory agencies. The final aim of the company is to move this technology till the first-in-human stage.
|